US20110097820A1 - Swab-Based Diagnostic Systems - Google Patents

Swab-Based Diagnostic Systems Download PDF

Info

Publication number
US20110097820A1
US20110097820A1 US12/982,452 US98245210A US2011097820A1 US 20110097820 A1 US20110097820 A1 US 20110097820A1 US 98245210 A US98245210 A US 98245210A US 2011097820 A1 US2011097820 A1 US 2011097820A1
Authority
US
United States
Prior art keywords
swab
component
detection
analyte
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/982,452
Inventor
Robert John Lyng
Jeffrey Eldon Fish
Rosann Marie Matthews Kaylor
Naveen Agarwal
Lei Huang
John Albert Shuty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kimberly Clark Worldwide Inc
Original Assignee
Kimberly Clark Worldwide Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly Clark Worldwide Inc filed Critical Kimberly Clark Worldwide Inc
Priority to US12/982,452 priority Critical patent/US20110097820A1/en
Publication of US20110097820A1 publication Critical patent/US20110097820A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045Devices for taking samples of body liquids
    • A61B10/0051Devices for taking samples of body liquids for taking saliva or sputum samples
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • A61B5/150022Source of blood for capillary blood or interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150206Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150251Collection chamber divided into at least two compartments, e.g. for division of samples
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150206Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150305Packages specially adapted for piercing devices or blood sampling devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150343Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150358Strips for collecting blood, e.g. absorbent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/157Devices characterised by integrated means for measuring characteristics of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B2010/0009Testing for drug or alcohol abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials

Definitions

  • Medical swabs are commonly used to collect biological specimens from a patient. Such medical swabs generally include a fibrous tip at one end of an elongated stick or shaft. Once a sample is collected, it may be transferred from the tip to a testing medium for performance of an immunoassay to determine the presence or absence of an analyte of interest.
  • Some systems known as “all-in-one” swab systems, have been developed that provide both the reagents for the immunoassay and the swab in a single, self-contained apparatus.
  • all-in-one one problem with such “all-in-one” systems is that the fluid contained within the apparatus often leaks out of the apparatus prior to use.
  • the method for using such devices typically involves several complicated steps that may lower the real-time efficacy of the device in detecting the presence or absence of the analyte.
  • a diagnostic test system for detecting the presence or absence of an analyte within a test sample.
  • the system comprises a swab and a detection unit.
  • the detection unit comprises a first component that is capable of receiving the swab.
  • the first component defines a sample port through which the swab is capable of being inserted.
  • a hydraulic seal e.g., o-ring
  • the first component defines an insertion chamber within which a fluid is capable of being retained.
  • a flexible packet is contained within the insertion chamber, the flexible packet being configured to retain the fluid.
  • the flexible packet may be formed from a film, metallic foil, or combinations thereof.
  • the flexible packet may have a thickness of less than about 0.05 inches, and in some embodiments, from about 0.0007 inches to about 0.02 inches.
  • the diagnostic test system also comprises a second component that defines a detection chamber within which an assay for detecting the presence or absence of the analyte is capable of being contained.
  • the first component is rotatable relative to the second component from an inactive position to an active position. In the inactive position, the fluid remains substantially retained within the insertion chamber. In the active position, the fluid may flow from the insertion chamber to the detection chamber and contact the assay.
  • the system further comprises a delivery channel that is also rotatable relative to the second component.
  • the second component may comprise a connection channel, wherein the delivery channel is capable of rotation into fluid communication with the connection channel so that the fluid flows from the insertion chamber, through the delivery channel, and into the connection channel.
  • the connection channel may be in fluid communication with the detection chamber.
  • a method for detecting the presence or absence of an analyte within a test sample comprises:
  • the method may further comprise determining the intensity of a detection signal generated at a detection zone of the assay, wherein the amount of the analyte within the test sample is determined from the detection signal.
  • the detection signal may be calibrated by a calibration signal generated at a calibration zone of the assay, wherein the amount of the analyte within the test sample is determined from the detection signal as calibrated by the calibration signal.
  • FIG. 1 is a perspective view of one embodiment of a diagnostic system of the present invention contained within a sealed package;
  • FIG. 2 is a perspective view of one embodiment of a diagnostic system of the present invention with the swab and test unit shown separately;
  • FIG. 3 is a perspective view depicting insertion of a swab into the test unit shown in FIG. 2 ;
  • FIG. 4 is a perspective view depicting rotation of the test unit shown in FIG. 2 ;
  • FIG. 5 is a cross-sectional view of the rotated test unit depicted in FIG. 4 ;
  • FIG. 6 is a perspective view of an assay that may be utilized in one embodiment of the present invention.
  • analytes generally refers to a substance to be detected.
  • analytes may include antigenic substances, haptens, antibodies, and combinations thereof.
  • Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including those administered for therapeutic purposes as well as those administered for illicit purposes), drug intermediaries or byproducts, bacteria, virus particles and metabolites of or antibodies to any of the above substances.
  • analytes include ferritin; creatinine kinase MB (CK-MB); digoxin; phenytoin; phenobarbitol; carbamazepine; vancomycin; gentamycin; theophylline; valproic acid; quinidine; luteinizing hormone (LH); follicle stimulating hormone (FSH); estradiol, progesterone; C-reactive protein; lipocalins; IgE antibodies; cytokines; vitamin B2 micro-globulin; glycated hemoglobin (Gly.
  • Hb cortisol; digitoxin; N-acetylprocainamide (NAPA); procainamide; antibodies to rubella, such as rubella-IgG and rubella IgM; antibodies to toxoplasmosis, such as toxoplasmosis IgG (Toxo-IgG) and toxoplasmosis IgM (Toxo-IgM); testosterone; salicylates; acetaminophen; hepatitis B virus surface antigen (HBsAg); antibodies to hepatitis B core antigen, such as anti-hepatitis B core antigen IgG and IgM (Anti-HBC); human immune deficiency virus 1 and 2 (HIV 1 and 2); human T-cell leukemia virus 1 and 2 (HTLV); hepatitis B e antigen (HBeAg); antibodies to hepatitis B e antigen (Anti-HBe); influenza virus; thyroid stimulating hormone (TSH); thyroxine (T4)
  • Drugs of abuse and controlled substances include, but are not intended to be limited to, amphetamine; methamphetamine; barbiturates, such as amobarbital, secobarbital, pentobarbital, phenobarbital, and barbital; benzodiazepines, such as librium and valium; cannabinoids, such as hashish and marijuana; cocaine; fentanyl; LSD; methaqualone; opiates, such as heroin, morphine, codeine, hydromorphone, hydrocodone, methadone, oxycodone, oxymorphone and opium; phencyclidine; and propoxyhene.
  • Other potential analytes may be described in U.S. Pat. No. 6,436,651 to Everhart, et al. and U.S. Pat. No. 4,366,241 to Tom et al.
  • test sample generally refers to a material suspected of containing the analyte.
  • the test sample may be used directly as obtained from the source or following a pretreatment to modify the character of the sample.
  • the test sample may be derived from any biological source, such as a physiological fluid, including, blood, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, vaginal fluid, amniotic fluid or the like.
  • the test sample may be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like.
  • Methods of treatment may involve filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, and the addition of reagents.
  • physiological fluids other liquid samples may be used such as water, food products and the like for the performance of environmental or food production assays.
  • a solid material suspected of containing the analyte may be used as the test sample. In some instances it may be beneficial to modify a solid test sample to form a liquid medium or to release the analyte.
  • the system 10 includes a swab 20 and a detection unit 30 into which the swab 20 may be inserted.
  • the swab 20 and/or detection unit 30 may optionally be sealed within a package 40 .
  • the configuration of the swab 20 (e.g., shape, size, materials, etc.) may generally vary as is well known in the art.
  • the swab 20 includes an elongated shaft 22 having a tip 24 of an absorbent material, such as cotton or rayon, at one end.
  • the tip 24 may also be formed from any other absorbent material known in the art, and may possess any desired shape and/or size.
  • any other swab construction, as well as any other type of test sample collection device may also be used in the present invention.
  • test sample collection devices are described in U.S. Pat. No. 6,541,194 to DiCesare and U.S. Pat. No. 6,548,018 to DiCesare, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • the detection unit 30 is generally of a size and shape to enable easy manual handling during use.
  • the detection unit 30 is substantially cylindrical in shape and is formed from at least two components, i.e., a first component 32 in fluid communication with a second component 34 .
  • the first and second components 32 and 34 may be made from any of a variety of materials, such as molded or blown plastic.
  • the first and second components 32 and 34 may also have a variety of different shapes and/or sizes.
  • the first component 32 has a generally cylindrical shape defined by an enclosure 80 that begins at a generally circular lower portion 82 and ends at the sample port 72 , wherein the width (e.g., diameter) of the component 32 is greater at the lower portion 82 than at the port 72 .
  • the second component 34 also has a generally cylindrical shape defined by an enclosure 84 that begins at a generally rectangular upper portion 86 and ends at the bottom end 88 of the detection unit 30 , wherein the width of the component 34 is greater at the upper portion 86 than at the bottom end 88 .
  • the detection unit 30 has a length that allows the swab absorbent tip 24 to be fully immersed in the reagents involved, which may be determined by the amount of reagent that is required.
  • Example volumes of the reagents are from about 50 to about 1000 microliters of fluid, with a typical amount being from about 100 to about 200 microliters.
  • the first component 32 defines a hollow insertion chamber 70 into which the swab 20 may be easily inserted via a sample port 72 .
  • the insertion chamber 70 may be provided with a fluid for mixing with a test sample contained on the swab 20 .
  • the fluid may be a buffer fluid, such as phosphate-buffered saline (PBS) (e.g., pH of 7.2) or 2-(N-morpholino) ethane sulfonic acid (MES) (e.g., pH of 5.3).
  • PBS phosphate-buffered saline
  • MES 2-(N-morpholino) ethane sulfonic acid
  • lysing agents such as for detection of microbes, e.g., Strep bacteria or yeasts
  • blocking agents e.g., bovine serum albumin
  • Still other optional materials that may be present within the fluid include labeled microparticles, detection probes, dyes, electrochemically-active agents (e.g., redox mediators), or other reagents used to create a signal for detection.
  • a top or cap may cover the sample port 72 .
  • the fluid within the insertion chamber 70 may also be retained within a thin, flexible packet (not shown) that is relatively resistant to diffusion of the fluid therethrough.
  • the packet may be formed from a variety of different materials, such as nonporous films, metallic seals (e.g., aluminum foil), etc.
  • thermoplastic polymers such as polyolefins (e.g., polyethylene, polypropylene, etc.), including homopolymers, copolymers, terpolymers and blends thereof; ethylene vinyl acetate; ethylene ethyl acrylate; ethylene acrylic acid; ethylene methyl acrylate; ethylene normal butyl acrylate; polyurethane; poly(ether-ester); poly(amid-ether) block copolymers; and the like.
  • suitable materials may include non-thermoplastic materials, silicone-based materials, other elastomeric materials, and so forth.
  • the thickness of the packet may be less than about 0.05 inches, in some embodiments between about 0.0003 inches to about 0.01 inches, and in some embodiments, between about 0.0007 inches to about 0.02 inches.
  • the first component 32 may utilize a hydraulic seal, such as o-rings 33 and 44 .
  • a hydraulic seal such as o-rings 33 and 44 .
  • the o-rings 33 and 44 provide a sealing fit between the outer surface of the swab 20 and the inner surface of the sample port 72 .
  • Other known hydraulic seals such as t-rings, B-rings, v-rings, etc., may also be used in the present invention. Using such seals, unwanted leakage from the sample port 72 may be inhibited.
  • the first component 32 is in fluid communication with a second component 34 .
  • the first component 32 generally rotates about a vertical axis A relative to the second component 34 .
  • Rotation may be accomplished manually, or through any well known automated device known in the art, including well known electronics, timing circuitry, etc. Due to the relative rotation of the components 32 and 34 , a user may easily manipulate the components as desired so that they are placed in direct engagement.
  • the detection unit 30 contains a delivery channel 38 that is also capable of rotation about a vertical axis A, which is formed integral with or separate from the first component 32 .
  • the delivery channel 38 is connected to the lower portion 82 of the first component 32 .
  • the first component 32 and delivery channel 38 are positioned so that fluid within the insertion chamber 70 does not flow to a detection chamber 73 of the second component 34 , i.e., inactive position.
  • this prohibitive function is accomplished by a barrier 36 , which may have any suitable size and/or shape, and be formed from any suitable material known in the art.
  • the barrier 36 is formed from a liquid-impermeable polymeric material.
  • the tip 24 of the swab 20 is contacted with a test sample suspected of containing the analyte of interest. Thereafter, as represented by the directional arrows of FIG. 3 , the tip 24 is inserted through the sample port 72 . Upon insertion, the o-rings 33 and 44 form a fitting seal around the elongated shaft 22 of the swab 20 . As described above, insertion of the tip 24 may also cause a thin, flexible packet (not shown) within the insertion chamber 70 to rupture, thereby releasing a fluid retained therein to mix with the test sample.
  • the first component 32 may then be placed into engagement with the second component 34 .
  • the engagement of the two components is illustrated in FIG. 4 .
  • the first component 32 is rotated in a counter-clockwise direction so that the delivery channel 38 is placed into communication with the connection channel 42 .
  • fluid may flow from the insertion chamber 70 into a detection chamber 73 of the second component 34 .
  • the fluid is allowed to contact an assay 60 for detecting the presence or absence of the analyte of interest.
  • an assay 60 that may be used in conjunction with the diagnostic test system 10 will now be described in more detail. It should be understood, however, that other assays are also contemplated by the present invention. In fact, the present invention is not limited to any particular assay configuration.
  • an assay 60 is illustrated that is an immunoassay.
  • Immunoassays utilize mechanisms of the immune systems, wherein antibodies are produced in response to the presence of antigens that are pathogenic or foreign to the organisms. These antibodies and antigens, i.e., immunoreactants, are capable of binding with one another, thereby causing a highly specific reaction mechanism that may be used to determine the presence or concentration of that particular antigen in a biological sample.
  • the assay 60 contains a porous membrane 63 optionally supported by a rigid material 61 .
  • the porous membrane 63 may be made from any of a variety of materials through which a fluid is capable of passing.
  • the materials used to form the porous membrane 63 may include, but are not limited to, natural, synthetic, or naturally occurring materials that are synthetically modified, such as polysaccharides (e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and nitrocellulose); polyether sulfone; polyethylene; nylon; polyvinylidene fluoride (PVDF); polyester; polypropylene; silica; inorganic materials, such as deactivated alumina, diatomaceous earth, MgSO 4 , or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copoly
  • the porous membrane 63 is formed from nitrocellulose and/or polyether sulfone materials.
  • nitrocellulose refers to nitric acid esters of cellulose, which may be nitrocellulose alone, or a mixed ester of nitric acid and other acids, such as aliphatic carboxylic acids having from 1 to 7 carbon atoms.
  • the assay 60 may also contain an absorbent pad 68 .
  • the absorbent pad 68 generally receives fluid that has migrated through the entire porous membrane 63 .
  • the absorbent pad 68 may assist in promoting capillary action and fluid flow through the membrane 63 .
  • the fluid from the connection channel 42 may first contact a sample pad (not shown) that is in fluid communication with the porous membrane 63 .
  • a sample pad (not shown) that is in fluid communication with the porous membrane 63 .
  • suitable materials that may be used to form the sample pad include, but are not limited to, nitrocellulose, cellulose, porous polyethylene pads, and glass fiber filter paper.
  • the sample pad may also contain one or more assay pretreatment reagents, either diffusively or non-diffusively attached thereto.
  • the test sample travels from the sample pad (not shown) to a conjugate pad 62 that is placed in communication with one end of the sampling pad.
  • the conjugate pad 62 is formed from a material through which a fluid is capable of passing.
  • the conjugate pad 62 is formed from glass fibers. Although only one conjugate pad 62 is shown, it should be understood that other conjugate pads may also be used in the present invention.
  • various detection probes may be applied to the conjugate pad 62 . While contained on the conjugate pad 62 , these detection probes remain available for binding with the analyte as it passes from the sampling pad through the conjugate pad 62 (or optionally in diluent). Upon binding with the analyte, the detection probes may later serve to identify the presence or absence of the analyte.
  • the detection probes may be used for both detection and calibration of the assay 60 . In alternative embodiments, however, separate calibration probes may be applied to the conjugate pad 62 for use in conjunction with the detection probes to facilitate simultaneous calibration and detection, thereby eliminating inaccuracies often created by conventional assay calibration systems.
  • the detection probes and/or the calibration probes may be applied together or separately at any location of the assay 60 , and need not be applied to the conjugate pad 62 . Further, it should also be understood that the detection probes and/or the calibration probes may be applied to the same or different conjugate pads.
  • the detection probes may be modified with certain specific binding members that are adhered thereto to form conjugated probes.
  • Specific binding members generally refer to a member of a specific binding pair, i.e., two different molecules where one of the molecules chemically and/or physically binds to the second molecule.
  • immunoreactive specific binding members may include antigens, haptens, aptamers, antibodies (primary or secondary), and complexes thereof, including those formed by recombinant DNA methods or peptide synthesis.
  • An antibody may be a monoclonal or polyclonal antibody, a recombinant protein or a mixture(s) or fragment(s) thereof, as well as a mixture of an antibody and other specific binding members.
  • the details of the preparation of such antibodies and their suitability for use as specific binding members are well known to those skilled in the art.
  • binding pairs include but are not limited to, biotin and avidin (or derivatives thereof), biotin and streptavidin, carbohydrates and lectins, complementary nucleotide sequences (including probe and capture nucleic acid sequences used in DNA hybridization assays to detect a target nucleic acid sequence), complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, hormone and hormone binding protein, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and so forth.
  • specific binding pairs may include members that are analogs of the original specific binding member.
  • a derivative or fragment of the analyte i.e., an analyte-analog, may be used so long as it has at least one epitope in common with the analyte.
  • the specific binding members may generally be attached to the detection probes using any of a variety of well-known techniques. For instance, covalent attachment of the specific binding members to the detection probes (e.g., particles) may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy and other reactive or linking functional groups, as well as residual free radicals and radical cations, through which a protein coupling reaction may be accomplished.
  • a surface functional group may also be incorporated as a functionalized co-monomer because the surface of the detection probe may contain a relatively high surface concentration of polar groups.
  • detection probes are often functionalized after synthesis, in certain cases, such as poly(thiophenol), the probes are capable of direct covalent linking with a protein without the need for further modification. Besides covalent bonding, other attachment techniques, such as physical adsorption, may also be utilized.
  • the fluid containing the test sample travels to the conjugate pad 62 , where the analyte mixes with detection probes modified with a specific binding member to form analyte complexes.
  • the conjugate pad 62 is in fluid communication with the porous membrane 63 , the complexes may migrate from the conjugate pad 62 to a detection zone 65 present on the porous membrane 63 .
  • the detection zone 65 may contain an immobilized receptive material that is generally capable of forming a chemical or physical bond with the analyte and/or complexes thereof (e.g., complexes of the analyte with the detection probes).
  • the receptive material may be a biological receptive material.
  • Such biological receptive materials are well known in the art and may include, but are not limited to, antigens, haptens, antibodies, protein A or G, avidin, streptavidin, and complexes thereof. In some cases, it is desired that these biological receptive materials are capable of binding to the analyte and/or the complexes of the analyte with the detection probes.
  • these receptive materials serve as stationary binding sites for the detection probe/analyte complexes.
  • the analytes such as antibodies, antigens, etc.
  • the analytes have two binding sites. Upon reaching the detection zone 65 , one of these binding sites is occupied by the specific binding member of the complexed probes. However, the free binding site of the analyte may bind to the immobilized receptive material. Upon being bound to the immobilized receptive material, the complexed probes form a new ternary sandwich complex.
  • the detection zone 65 may generally provide any number of distinct detection regions so that a user may better determine the concentration of a particular analyte within a test sample. Each region may contain the same receptive materials, or may contain different receptive materials for capturing multiple analytes.
  • the detection zone 65 may include two or more distinct detection regions (e.g., lines, dots, etc.).
  • the detection regions may be disposed in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the assay 60 .
  • the detection regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample through the assay device.
  • the assay 60 may also include a calibration zone 64 .
  • the calibration zone 64 is formed on the porous membrane 63 and is positioned downstream from the detection zone 65 .
  • the calibration zone 64 is provided with a receptive material that is capable of binding to any remaining uncaptured detection probes and/or calibration probes that pass through the length of the membrane 63 .
  • any uncaptured probes that do not bind to the analyte migrate through the detection zone 65 and enter the calibration zone 64 of the porous membrane 63 .
  • these uncaptured probes then bind to the receptive materials.
  • the receptive materials utilized in the calibration zone 64 may be the same or different than the receptive materials used in the detection zone 65 .
  • the receptive material may include a polyelectrolyte that may bind to the uncaptured probes.
  • the polyelectrolytes may have a net positive or negative charge, as well as a net charge that is generally neutral.
  • some suitable examples of polyelectrolytes having a net positive charge include, but are not limited to, polylysine (commercially available from Sigma-Aldrich Chemical Co., Inc. of St.
  • CelQuat® SC-230M or H-100 available from National Starch & Chemical, Inc., which are cellulosic derivatives containing a quaternary ammonium water-soluble monomer, may be utilized.
  • polyelectrolytes having a net negative charge include, but are not limited to, polyacrylic acids, such as poly(ethylene-co-methacrylic acid, sodium salt), and the like. It should also be understood that other polyelectrolytes may also be utilized in the present invention, such as amphiphilic polyelectrolytes (i.e., having polar and non-polar portions). For instance, some examples of suitable amphiphilic polyelectrolytes include, but are not limited to, poly(styryl-b-N-methyl 2-vinyl pyridinium iodide) and poly(styryl-b-acrylic acid), both of which are available from Polymer Source, Inc. of Dorval, Canada.
  • the calibration zone 64 may also provide any number of distinct calibration regions in any direction so that a user may better determine the concentration of a particular analyte within a test sample.
  • the calibration regions may be pre-loaded on the porous membrane 63 with different amounts of the binder so that a different signal intensity is generated by each calibration region upon migration of the uncaptured probes.
  • the overall amount of receptive material within each calibration region may be varied by utilizing calibration regions of different sizes and/or by varying the concentration or volume of the binder in each calibration region. If desired, an excess of probe molecules may be employed in the assay 60 so that each calibration region reaches its full and predetermined potential for signal intensity.
  • the amount of uncaptured probes that are deposited upon calibration regions are predetermined because the amount of the binder employed on the calibration regions is set at a predetermined and known level.
  • the signal of the probes at the detection and calibration zones 65 and 64 may be measured visually or through other methods of detection (e.g., instruments).
  • a portion of the enclosure 84 of the second component 34 may optionally be provided with a window or other viewing area (not shown) as is well known in the art so that a user may readily observe the assay 60 .
  • the membrane 63 may also define a control zone (not shown) that gives a signal to the user that the assay is performing properly.
  • the control zone (not shown) may contain an immobilized receptive material that is generally capable of forming a chemical and/or physical bond with probes or with the receptive material immobilized on the probes.
  • receptive materials include, but are not limited to, antigens, haptens, antibodies, protein A or G, avidin, streptavidin, secondary antibodies, and complexes thereof.
  • control zone receptive material may also include a polyelectrolyte, such as described above, that may bind to uncaptured probes. Because the receptive material at the control zone is only specific for probes, a signal forms regardless of whether the analyte is present.
  • the control zone may be positioned at any location along the membrane 63 , but is preferably positioned upstream from the detection zone 65 .
  • Various formats may be used to test for the presence or absence of an analyte using the assay 60 .
  • a “sandwich” format is utilized.
  • Other examples of such sandwich-type assays are described by U.S. Pat. No. 4,168,146 to Grubb, et al. and U.S. Pat. No. 4,366,241 to Tom, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • other formats such as “competitive” formats, may also be utilized.
  • the labeled probe is generally conjugated with a molecule that is identical to, or an analogue of, the analyte.
  • the labeled probe competes with the analyte of interest for the available receptive material.
  • Competitive assays are typically used for detection of analytes such as haptens, each hapten being monovalent and capable of binding only one antibody molecule. Examples of competitive immunoassay devices are described in U.S. Pat. No. 4,235,601 to Deutsch, et al., U.S. Pat. No. 4,442,204 to Liotta, and U.S. Pat. No. 5,208,535 to Buechler, et al., which are incorporated herein in their entirety by reference thereto for all purposes. Various other device configurations and/or assay formats are also described in U.S. Pat. No.
  • the assay 60 may also be an electrochemical affinity assay, which detects an electrochemical reaction between an analyte (or complex thereof) and a capture ligand on an electrode strip.
  • electrochemical affinity assay detects an electrochemical reaction between an analyte (or complex thereof) and a capture ligand on an electrode strip.
  • various electrochemical assays are described in U.S. Pat. No. 5,508,171 to Walling, et al.; U.S. Pat. No. 5,534,132 to Vreeke, et al; U.S. Pat. No. 6,241,863 to Monbouquette; U.S. Pat. No. 6,270,637 to Crismore, et al.; U.S. Pat. No. 6,281,006 to Heller, et al.; and U.S. Pat. No. 6,461,496 to Feldman, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • the system of the present invention provides a relatively simple, compact and cost-efficient device for facilitated collecting and substantially immediate on-site testing of analytes.
  • the system enables quick and easy specimen collection with a swab, followed by prompt placement of the collected specimen into a test unit that is substantially closed and sealed to minimize risk of direct personnel contact with the collected organism. Thereafter, the test unit may be manipulated to analyze the collected specimen and provide a visible test result. This visible test result may be readily observed by the person performing the test in a prompt manner and under test conditions conducive to highly reliable and consistent test results. After initial specimen collection, human contact with the specimen is thus substantially precluded throughout the test protocol, and the entire device with the collected specimen safely contained therein may be discarded as a unit when the test is concluded.

Abstract

A diagnostic test system for detecting the presence or absence of an analyte within a test sample is provided. For instance, the system may include a swab and a detection unit. The detection unit includes a first component that is capable of receiving the swab, the first component defining an insertion chamber within which a fluid is capable of being retained. The detection unit also includes a second component that defines a detection chamber within which an assay for detecting the presence or absence of the analyte is capable of being contained. The first component is rotatable relative to the second component from an inactive position to an active position. In the inactive position, the fluid remains substantially contained within the insertion chamber. In the active position, the fluid may flow from the insertion chamber to the detection chamber and contact the assay.

Description

    BACKGROUND OF THE INVENTION
  • Medical swabs are commonly used to collect biological specimens from a patient. Such medical swabs generally include a fibrous tip at one end of an elongated stick or shaft. Once a sample is collected, it may be transferred from the tip to a testing medium for performance of an immunoassay to determine the presence or absence of an analyte of interest. Some systems, known as “all-in-one” swab systems, have been developed that provide both the reagents for the immunoassay and the swab in a single, self-contained apparatus. However, one problem with such “all-in-one” systems is that the fluid contained within the apparatus often leaks out of the apparatus prior to use. In addition, the method for using such devices typically involves several complicated steps that may lower the real-time efficacy of the device in detecting the presence or absence of the analyte.
  • As such a need currently exits for a swab-based device that is effective in detecting the presence of an analyte in a simple manner.
  • SUMMARY OF THE INVENTION
  • In accordance with one embodiment of the present invention, a diagnostic test system is disclosed for detecting the presence or absence of an analyte within a test sample. The system comprises a swab and a detection unit. The detection unit comprises a first component that is capable of receiving the swab. In one embodiment, the first component defines a sample port through which the swab is capable of being inserted. A hydraulic seal (e.g., o-ring) may form a sealing fit between the sample port and the swab. The first component defines an insertion chamber within which a fluid is capable of being retained. In one embodiment, a flexible packet is contained within the insertion chamber, the flexible packet being configured to retain the fluid. For example, the flexible packet may be formed from a film, metallic foil, or combinations thereof. The flexible packet may have a thickness of less than about 0.05 inches, and in some embodiments, from about 0.0007 inches to about 0.02 inches.
  • The diagnostic test system also comprises a second component that defines a detection chamber within which an assay for detecting the presence or absence of the analyte is capable of being contained. The first component is rotatable relative to the second component from an inactive position to an active position. In the inactive position, the fluid remains substantially retained within the insertion chamber. In the active position, the fluid may flow from the insertion chamber to the detection chamber and contact the assay. In one embodiment, for instance, the system further comprises a delivery channel that is also rotatable relative to the second component. The second component may comprise a connection channel, wherein the delivery channel is capable of rotation into fluid communication with the connection channel so that the fluid flows from the insertion chamber, through the delivery channel, and into the connection channel. The connection channel may be in fluid communication with the detection chamber.
  • In accordance with another embodiment of the present invention, a method is disclosed for detecting the presence or absence of an analyte within a test sample. The method comprises:
  • i) providing a diagnostic test system, the system comprising a swab and a detection unit, the detection unit comprising:
      • a) a first component that is capable of receiving the swab, the first component defining an insertion chamber within which a fluid is retained; and
      • b) a second component defining a detection chamber within which an assay for detecting the presence or absence of the analyte is capable of being contained;
  • ii) contacting the swab with the test sample;
  • iii) inserting the swab into the insertion chamber of the first component so that the swab contacts the fluid; and
  • iv) rotating the first component relative to the second component so that the fluid flows from the insertion chamber to the detection chamber and contacts the assay. The method may further comprise determining the intensity of a detection signal generated at a detection zone of the assay, wherein the amount of the analyte within the test sample is determined from the detection signal. In addition, the detection signal may be calibrated by a calibration signal generated at a calibration zone of the assay, wherein the amount of the analyte within the test sample is determined from the detection signal as calibrated by the calibration signal.
  • Other features and aspects of the present invention are discussed in greater detail below.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A full and enabling disclosure of the present invention, including the best mode thereof, directed to one of ordinary skill in the art, is set forth more particularly in the remainder of the specification, which makes reference to the appended figures in which:
  • FIG. 1 is a perspective view of one embodiment of a diagnostic system of the present invention contained within a sealed package;
  • FIG. 2 is a perspective view of one embodiment of a diagnostic system of the present invention with the swab and test unit shown separately;
  • FIG. 3 is a perspective view depicting insertion of a swab into the test unit shown in FIG. 2;
  • FIG. 4 is a perspective view depicting rotation of the test unit shown in FIG. 2;
  • FIG. 5 is a cross-sectional view of the rotated test unit depicted in FIG. 4; and
  • FIG. 6 is a perspective view of an assay that may be utilized in one embodiment of the present invention.
  • Repeat use of reference characters in the present specification and drawings is intended to represent same or analogous features or elements of the invention.
  • DETAILED DESCRIPTION OF REPRESENTATIVE EMBODIMENTS Definitions
  • As used herein, the term “analyte” generally refers to a substance to be detected. For instance, analytes may include antigenic substances, haptens, antibodies, and combinations thereof. Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including those administered for therapeutic purposes as well as those administered for illicit purposes), drug intermediaries or byproducts, bacteria, virus particles and metabolites of or antibodies to any of the above substances. Specific examples of some analytes include ferritin; creatinine kinase MB (CK-MB); digoxin; phenytoin; phenobarbitol; carbamazepine; vancomycin; gentamycin; theophylline; valproic acid; quinidine; luteinizing hormone (LH); follicle stimulating hormone (FSH); estradiol, progesterone; C-reactive protein; lipocalins; IgE antibodies; cytokines; vitamin B2 micro-globulin; glycated hemoglobin (Gly. Hb); cortisol; digitoxin; N-acetylprocainamide (NAPA); procainamide; antibodies to rubella, such as rubella-IgG and rubella IgM; antibodies to toxoplasmosis, such as toxoplasmosis IgG (Toxo-IgG) and toxoplasmosis IgM (Toxo-IgM); testosterone; salicylates; acetaminophen; hepatitis B virus surface antigen (HBsAg); antibodies to hepatitis B core antigen, such as anti-hepatitis B core antigen IgG and IgM (Anti-HBC); human immune deficiency virus 1 and 2 (HIV 1 and 2); human T-cell leukemia virus 1 and 2 (HTLV); hepatitis B e antigen (HBeAg); antibodies to hepatitis B e antigen (Anti-HBe); influenza virus; thyroid stimulating hormone (TSH); thyroxine (T4); total triiodothyronine (Total T3); free triiodothyronine (Free T3); carcinoembryoic antigen (CEA); lipoproteins, cholesterol, and triglycerides; and alpha fetoprotein (AFP). Drugs of abuse and controlled substances include, but are not intended to be limited to, amphetamine; methamphetamine; barbiturates, such as amobarbital, secobarbital, pentobarbital, phenobarbital, and barbital; benzodiazepines, such as librium and valium; cannabinoids, such as hashish and marijuana; cocaine; fentanyl; LSD; methaqualone; opiates, such as heroin, morphine, codeine, hydromorphone, hydrocodone, methadone, oxycodone, oxymorphone and opium; phencyclidine; and propoxyhene. Other potential analytes may be described in U.S. Pat. No. 6,436,651 to Everhart, et al. and U.S. Pat. No. 4,366,241 to Tom et al.
  • As used herein, the term “test sample” generally refers to a material suspected of containing the analyte. The test sample may be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The test sample may be derived from any biological source, such as a physiological fluid, including, blood, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, vaginal fluid, amniotic fluid or the like. The test sample may be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment may involve filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, and the addition of reagents. Besides physiological fluids, other liquid samples may be used such as water, food products and the like for the performance of environmental or food production assays. In addition, a solid material suspected of containing the analyte may be used as the test sample. In some instances it may be beneficial to modify a solid test sample to form a liquid medium or to release the analyte.
  • DETAILED DESCRIPTION
  • Reference now will be made in detail to various embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation of the invention, not limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, may be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention covers such modifications and variations as come within the scope of the appended claims and their equivalents.
  • Referring to FIGS. 1-2, for instance, one embodiment of a diagnostic test system 10 that may be formed according to the present invention will now be described in more detail. As shown, the system 10 includes a swab 20 and a detection unit 30 into which the swab 20 may be inserted. The swab 20 and/or detection unit 30 may optionally be sealed within a package 40. The configuration of the swab 20 (e.g., shape, size, materials, etc.) may generally vary as is well known in the art. For example, in the illustrated embodiment, the swab 20 includes an elongated shaft 22 having a tip 24 of an absorbent material, such as cotton or rayon, at one end. It should be understood that the tip 24 may also be formed from any other absorbent material known in the art, and may possess any desired shape and/or size. Further, any other swab construction, as well as any other type of test sample collection device, may also be used in the present invention. For example, other types of test sample collection devices are described in U.S. Pat. No. 6,541,194 to DiCesare and U.S. Pat. No. 6,548,018 to DiCesare, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • The detection unit 30 is generally of a size and shape to enable easy manual handling during use. In the illustrated embodiment, for example, the detection unit 30 is substantially cylindrical in shape and is formed from at least two components, i.e., a first component 32 in fluid communication with a second component 34. The first and second components 32 and 34 may be made from any of a variety of materials, such as molded or blown plastic. In addition, the first and second components 32 and 34 may also have a variety of different shapes and/or sizes. In the illustrated embodiment, for instance, the first component 32 has a generally cylindrical shape defined by an enclosure 80 that begins at a generally circular lower portion 82 and ends at the sample port 72, wherein the width (e.g., diameter) of the component 32 is greater at the lower portion 82 than at the port 72. Similarly, the second component 34 also has a generally cylindrical shape defined by an enclosure 84 that begins at a generally rectangular upper portion 86 and ends at the bottom end 88 of the detection unit 30, wherein the width of the component 34 is greater at the upper portion 86 than at the bottom end 88. The detection unit 30 has a length that allows the swab absorbent tip 24 to be fully immersed in the reagents involved, which may be determined by the amount of reagent that is required. Example volumes of the reagents are from about 50 to about 1000 microliters of fluid, with a typical amount being from about 100 to about 200 microliters.
  • The first component 32 defines a hollow insertion chamber 70 into which the swab 20 may be easily inserted via a sample port 72. The insertion chamber 70 may be provided with a fluid for mixing with a test sample contained on the swab 20. For example, the fluid may be a buffer fluid, such as phosphate-buffered saline (PBS) (e.g., pH of 7.2) or 2-(N-morpholino) ethane sulfonic acid (MES) (e.g., pH of 5.3). Other types of fluids that may be contained within the device include detergents, salts, lysing agents (such as for detection of microbes, e.g., Strep bacteria or yeasts), blocking agents (e.g., bovine serum albumin), other proteins, and so forth. Still other optional materials that may be present within the fluid include labeled microparticles, detection probes, dyes, electrochemically-active agents (e.g., redox mediators), or other reagents used to create a signal for detection.
  • To inhibit leaking of the fluid from the sample port 72, various mechanisms may be employed. For example, prior to insertion of the swab 20, a top or cap may cover the sample port 72. In addition, the fluid within the insertion chamber 70 may also be retained within a thin, flexible packet (not shown) that is relatively resistant to diffusion of the fluid therethrough. The packet may be formed from a variety of different materials, such as nonporous films, metallic seals (e.g., aluminum foil), etc. Some suitable materials used in the fabrication of films for forming the packet may include thermoplastic polymers, such as polyolefins (e.g., polyethylene, polypropylene, etc.), including homopolymers, copolymers, terpolymers and blends thereof; ethylene vinyl acetate; ethylene ethyl acrylate; ethylene acrylic acid; ethylene methyl acrylate; ethylene normal butyl acrylate; polyurethane; poly(ether-ester); poly(amid-ether) block copolymers; and the like. Other suitable materials may include non-thermoplastic materials, silicone-based materials, other elastomeric materials, and so forth. In some embodiments, it is desired to minimize the thickness of the packet so that a user may easily rupture it with the swab 20. In such instances, the thickness of the packet may be less than about 0.05 inches, in some embodiments between about 0.0003 inches to about 0.01 inches, and in some embodiments, between about 0.0007 inches to about 0.02 inches.
  • In addition, mechanisms may also be employed to inhibit fluid leakage from the sample port 72 after insertion of the swab 20 into the insertion chamber 70. For example, as shown in FIG. 2, the first component 32 may utilize a hydraulic seal, such as o- rings 33 and 44. As is well known in the art, the o- rings 33 and 44 provide a sealing fit between the outer surface of the swab 20 and the inner surface of the sample port 72. Other known hydraulic seals, such as t-rings, B-rings, v-rings, etc., may also be used in the present invention. Using such seals, unwanted leakage from the sample port 72 may be inhibited.
  • As indicated above, the first component 32 is in fluid communication with a second component 34. In this embodiment, for example, the first component 32 generally rotates about a vertical axis A relative to the second component 34. Rotation may be accomplished manually, or through any well known automated device known in the art, including well known electronics, timing circuitry, etc. Due to the relative rotation of the components 32 and 34, a user may easily manipulate the components as desired so that they are placed in direct engagement. Namely, the detection unit 30 contains a delivery channel 38 that is also capable of rotation about a vertical axis A, which is formed integral with or separate from the first component 32. In the illustrated embodiment, for example, the delivery channel 38 is connected to the lower portion 82 of the first component 32.
  • When not in use, the first component 32 and delivery channel 38 are positioned so that fluid within the insertion chamber 70 does not flow to a detection chamber 73 of the second component 34, i.e., inactive position. In one embodiment, for instance, this prohibitive function is accomplished by a barrier 36, which may have any suitable size and/or shape, and be formed from any suitable material known in the art. For example, in one embodiment, the barrier 36 is formed from a liquid-impermeable polymeric material. To engage the first component 32 with the second component 34, the first component 32 is rotated so that the delivery channel 38 is positioned adjacent to a connection channel 42 of the second component 34, i.e., active position. Consequently, fluid is capable of flowing from the chamber 70, through the delivery channel 38 and connection channel 42, and finally into the detection chamber 73.
  • Referring to FIGS. 3-5, the operation of the diagnostic test system 10 will now be described in more detail. Initially, the tip 24 of the swab 20 is contacted with a test sample suspected of containing the analyte of interest. Thereafter, as represented by the directional arrows of FIG. 3, the tip 24 is inserted through the sample port 72. Upon insertion, the o- rings 33 and 44 form a fitting seal around the elongated shaft 22 of the swab 20. As described above, insertion of the tip 24 may also cause a thin, flexible packet (not shown) within the insertion chamber 70 to rupture, thereby releasing a fluid retained therein to mix with the test sample. Once the swab 20 is inserted and optionally allowed to mix with a fluid within the insertion chamber 70, the first component 32 may then be placed into engagement with the second component 34. The engagement of the two components is illustrated in FIG. 4. Specifically, in this embodiment, the first component 32 is rotated in a counter-clockwise direction so that the delivery channel 38 is placed into communication with the connection channel 42. In this manner, fluid may flow from the insertion chamber 70 into a detection chamber 73 of the second component 34. Once in the detection chamber 73, the fluid is allowed to contact an assay 60 for detecting the presence or absence of the analyte of interest.
  • For purposes of illustration only, various examples of an assay 60 that may be used in conjunction with the diagnostic test system 10 will now be described in more detail. It should be understood, however, that other assays are also contemplated by the present invention. In fact, the present invention is not limited to any particular assay configuration. In this regard, referring to FIG. 6, one embodiment of an assay 60 is illustrated that is an immunoassay. Immunoassays utilize mechanisms of the immune systems, wherein antibodies are produced in response to the presence of antigens that are pathogenic or foreign to the organisms. These antibodies and antigens, i.e., immunoreactants, are capable of binding with one another, thereby causing a highly specific reaction mechanism that may be used to determine the presence or concentration of that particular antigen in a biological sample.
  • In the illustrated embodiment, the assay 60 contains a porous membrane 63 optionally supported by a rigid material 61. In general, the porous membrane 63 may be made from any of a variety of materials through which a fluid is capable of passing. For example, the materials used to form the porous membrane 63 may include, but are not limited to, natural, synthetic, or naturally occurring materials that are synthetically modified, such as polysaccharides (e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and nitrocellulose); polyether sulfone; polyethylene; nylon; polyvinylidene fluoride (PVDF); polyester; polypropylene; silica; inorganic materials, such as deactivated alumina, diatomaceous earth, MgSO4, or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon or rayon); porous gels, such as silica gel, agarose, dextran, and gelatin; polymeric films, such as polyacrylamide; and the like. In one particular embodiment, the porous membrane 63 is formed from nitrocellulose and/or polyether sulfone materials. It should be understood that the term “nitrocellulose” refers to nitric acid esters of cellulose, which may be nitrocellulose alone, or a mixed ester of nitric acid and other acids, such as aliphatic carboxylic acids having from 1 to 7 carbon atoms.
  • The assay 60 may also contain an absorbent pad 68. The absorbent pad 68 generally receives fluid that has migrated through the entire porous membrane 63. As is well known in the art, the absorbent pad 68 may assist in promoting capillary action and fluid flow through the membrane 63. In some embodiments, the fluid from the connection channel 42 (see FIGS. 1-5) may first contact a sample pad (not shown) that is in fluid communication with the porous membrane 63. Some suitable materials that may be used to form the sample pad include, but are not limited to, nitrocellulose, cellulose, porous polyethylene pads, and glass fiber filter paper. If desired, the sample pad may also contain one or more assay pretreatment reagents, either diffusively or non-diffusively attached thereto.
  • In the illustrated embodiment, the test sample travels from the sample pad (not shown) to a conjugate pad 62 that is placed in communication with one end of the sampling pad. The conjugate pad 62 is formed from a material through which a fluid is capable of passing. For example, in one embodiment, the conjugate pad 62 is formed from glass fibers. Although only one conjugate pad 62 is shown, it should be understood that other conjugate pads may also be used in the present invention.
  • To facilitate detection of the presence or absence of an analyte within the test sample, various detection probes may be applied to the conjugate pad 62. While contained on the conjugate pad 62, these detection probes remain available for binding with the analyte as it passes from the sampling pad through the conjugate pad 62 (or optionally in diluent). Upon binding with the analyte, the detection probes may later serve to identify the presence or absence of the analyte. The detection probes may be used for both detection and calibration of the assay 60. In alternative embodiments, however, separate calibration probes may be applied to the conjugate pad 62 for use in conjunction with the detection probes to facilitate simultaneous calibration and detection, thereby eliminating inaccuracies often created by conventional assay calibration systems. It should be understood, however, that the detection probes and/or the calibration probes may be applied together or separately at any location of the assay 60, and need not be applied to the conjugate pad 62. Further, it should also be understood that the detection probes and/or the calibration probes may be applied to the same or different conjugate pads.
  • In some instances, it is desired to modify the detection probes in some manner so that they are more readily able to bind to the analyte. In such instances, the detection probes may be modified with certain specific binding members that are adhered thereto to form conjugated probes. Specific binding members generally refer to a member of a specific binding pair, i.e., two different molecules where one of the molecules chemically and/or physically binds to the second molecule. For instance, immunoreactive specific binding members may include antigens, haptens, aptamers, antibodies (primary or secondary), and complexes thereof, including those formed by recombinant DNA methods or peptide synthesis. An antibody may be a monoclonal or polyclonal antibody, a recombinant protein or a mixture(s) or fragment(s) thereof, as well as a mixture of an antibody and other specific binding members. The details of the preparation of such antibodies and their suitability for use as specific binding members are well known to those skilled in the art. Other common specific binding pairs include but are not limited to, biotin and avidin (or derivatives thereof), biotin and streptavidin, carbohydrates and lectins, complementary nucleotide sequences (including probe and capture nucleic acid sequences used in DNA hybridization assays to detect a target nucleic acid sequence), complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, hormone and hormone binding protein, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and so forth. Furthermore, specific binding pairs may include members that are analogs of the original specific binding member. For example, a derivative or fragment of the analyte, i.e., an analyte-analog, may be used so long as it has at least one epitope in common with the analyte.
  • The specific binding members may generally be attached to the detection probes using any of a variety of well-known techniques. For instance, covalent attachment of the specific binding members to the detection probes (e.g., particles) may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy and other reactive or linking functional groups, as well as residual free radicals and radical cations, through which a protein coupling reaction may be accomplished. A surface functional group may also be incorporated as a functionalized co-monomer because the surface of the detection probe may contain a relatively high surface concentration of polar groups. In addition, although detection probes are often functionalized after synthesis, in certain cases, such as poly(thiophenol), the probes are capable of direct covalent linking with a protein without the need for further modification. Besides covalent bonding, other attachment techniques, such as physical adsorption, may also be utilized.
  • In one embodiment, for instance, the fluid containing the test sample travels to the conjugate pad 62, where the analyte mixes with detection probes modified with a specific binding member to form analyte complexes. Because the conjugate pad 62 is in fluid communication with the porous membrane 63, the complexes may migrate from the conjugate pad 62 to a detection zone 65 present on the porous membrane 63. The detection zone 65 may contain an immobilized receptive material that is generally capable of forming a chemical or physical bond with the analyte and/or complexes thereof (e.g., complexes of the analyte with the detection probes). In some embodiments, the receptive material may be a biological receptive material. Such biological receptive materials are well known in the art and may include, but are not limited to, antigens, haptens, antibodies, protein A or G, avidin, streptavidin, and complexes thereof. In some cases, it is desired that these biological receptive materials are capable of binding to the analyte and/or the complexes of the analyte with the detection probes.
  • These receptive materials serve as stationary binding sites for the detection probe/analyte complexes. In some instances, the analytes, such as antibodies, antigens, etc., have two binding sites. Upon reaching the detection zone 65, one of these binding sites is occupied by the specific binding member of the complexed probes. However, the free binding site of the analyte may bind to the immobilized receptive material. Upon being bound to the immobilized receptive material, the complexed probes form a new ternary sandwich complex.
  • The detection zone 65 may generally provide any number of distinct detection regions so that a user may better determine the concentration of a particular analyte within a test sample. Each region may contain the same receptive materials, or may contain different receptive materials for capturing multiple analytes. For example, the detection zone 65 may include two or more distinct detection regions (e.g., lines, dots, etc.). The detection regions may be disposed in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the assay 60. Likewise, in some embodiments, the detection regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample through the assay device.
  • Although the detection zone 65 may indicate the presence of an analyte, it is often difficult to determine the relative concentration of the analyte within the test sample using solely a detection zone 65. Thus, the assay 60 may also include a calibration zone 64. In this embodiment, the calibration zone 64 is formed on the porous membrane 63 and is positioned downstream from the detection zone 65. The calibration zone 64 is provided with a receptive material that is capable of binding to any remaining uncaptured detection probes and/or calibration probes that pass through the length of the membrane 63. In particular, upon being contacted with the test sample, any uncaptured probes that do not bind to the analyte migrate through the detection zone 65 and enter the calibration zone 64 of the porous membrane 63. At the calibration zone 64, these uncaptured probes then bind to the receptive materials.
  • The receptive materials utilized in the calibration zone 64 may be the same or different than the receptive materials used in the detection zone 65. For instance, in some embodiments, the receptive material may include a polyelectrolyte that may bind to the uncaptured probes. The polyelectrolytes may have a net positive or negative charge, as well as a net charge that is generally neutral. For instance, some suitable examples of polyelectrolytes having a net positive charge include, but are not limited to, polylysine (commercially available from Sigma-Aldrich Chemical Co., Inc. of St. Louis, Mo.), polyethylenimine; epichlorohydrin-functionalized polyamines and/or polyamidoamines, such as poly(dimethylamine-co-epichlorohydrin); polydiallyldimethyl-ammonium chloride; cationic cellulose derivatives, such as cellulose copolymers or cellulose derivatives grafted with a quaternary ammonium water-soluble monomer; and the like. In one particular embodiment, CelQuat® SC-230M or H-100 (available from National Starch & Chemical, Inc.), which are cellulosic derivatives containing a quaternary ammonium water-soluble monomer, may be utilized. Moreover, some suitable examples of polyelectrolytes having a net negative charge include, but are not limited to, polyacrylic acids, such as poly(ethylene-co-methacrylic acid, sodium salt), and the like. It should also be understood that other polyelectrolytes may also be utilized in the present invention, such as amphiphilic polyelectrolytes (i.e., having polar and non-polar portions). For instance, some examples of suitable amphiphilic polyelectrolytes include, but are not limited to, poly(styryl-b-N-methyl 2-vinyl pyridinium iodide) and poly(styryl-b-acrylic acid), both of which are available from Polymer Source, Inc. of Dorval, Canada.
  • Similar to the detection zone 65, the calibration zone 64 may also provide any number of distinct calibration regions in any direction so that a user may better determine the concentration of a particular analyte within a test sample. The calibration regions may be pre-loaded on the porous membrane 63 with different amounts of the binder so that a different signal intensity is generated by each calibration region upon migration of the uncaptured probes. The overall amount of receptive material within each calibration region may be varied by utilizing calibration regions of different sizes and/or by varying the concentration or volume of the binder in each calibration region. If desired, an excess of probe molecules may be employed in the assay 60 so that each calibration region reaches its full and predetermined potential for signal intensity. That is, the amount of uncaptured probes that are deposited upon calibration regions are predetermined because the amount of the binder employed on the calibration regions is set at a predetermined and known level. Once captured, the signal of the probes at the detection and calibration zones 65 and 64 may be measured visually or through other methods of detection (e.g., instruments). When determined visually, for instance, a portion of the enclosure 84 of the second component 34 may optionally be provided with a window or other viewing area (not shown) as is well known in the art so that a user may readily observe the assay 60.
  • In some cases, the membrane 63 may also define a control zone (not shown) that gives a signal to the user that the assay is performing properly. For instance, the control zone (not shown) may contain an immobilized receptive material that is generally capable of forming a chemical and/or physical bond with probes or with the receptive material immobilized on the probes. Some examples of such receptive materials include, but are not limited to, antigens, haptens, antibodies, protein A or G, avidin, streptavidin, secondary antibodies, and complexes thereof. In addition, it may also be desired to utilize various non-biological materials for the control zone receptive material. For instance, in some embodiments, the control zone receptive material may also include a polyelectrolyte, such as described above, that may bind to uncaptured probes. Because the receptive material at the control zone is only specific for probes, a signal forms regardless of whether the analyte is present. The control zone may be positioned at any location along the membrane 63, but is preferably positioned upstream from the detection zone 65.
  • Various formats may be used to test for the presence or absence of an analyte using the assay 60. For instance, in the embodiment described above, a “sandwich” format is utilized. Other examples of such sandwich-type assays are described by U.S. Pat. No. 4,168,146 to Grubb, et al. and U.S. Pat. No. 4,366,241 to Tom, et al., which are incorporated herein in their entirety by reference thereto for all purposes. In addition, other formats, such as “competitive” formats, may also be utilized. In a competitive assay, the labeled probe is generally conjugated with a molecule that is identical to, or an analogue of, the analyte. Thus, the labeled probe competes with the analyte of interest for the available receptive material. Competitive assays are typically used for detection of analytes such as haptens, each hapten being monovalent and capable of binding only one antibody molecule. Examples of competitive immunoassay devices are described in U.S. Pat. No. 4,235,601 to Deutsch, et al., U.S. Pat. No. 4,442,204 to Liotta, and U.S. Pat. No. 5,208,535 to Buechler, et al., which are incorporated herein in their entirety by reference thereto for all purposes. Various other device configurations and/or assay formats are also described in U.S. Pat. No. 5,395,754 to Lambotte, et al.; U.S. Pat. No. 5,670,381 to Jou, et al.; and U.S. Pat. No. 6,194,220 to Malick, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • In addition, it should be understood that any known detection technique may be utilized in the present invention. For example, as is well known in the art, the assay 60 may also be an electrochemical affinity assay, which detects an electrochemical reaction between an analyte (or complex thereof) and a capture ligand on an electrode strip. For example, various electrochemical assays are described in U.S. Pat. No. 5,508,171 to Walling, et al.; U.S. Pat. No. 5,534,132 to Vreeke, et al; U.S. Pat. No. 6,241,863 to Monbouquette; U.S. Pat. No. 6,270,637 to Crismore, et al.; U.S. Pat. No. 6,281,006 to Heller, et al.; and U.S. Pat. No. 6,461,496 to Feldman, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • It has been discovered that the system of the present invention provides a relatively simple, compact and cost-efficient device for facilitated collecting and substantially immediate on-site testing of analytes. The system enables quick and easy specimen collection with a swab, followed by prompt placement of the collected specimen into a test unit that is substantially closed and sealed to minimize risk of direct personnel contact with the collected organism. Thereafter, the test unit may be manipulated to analyze the collected specimen and provide a visible test result. This visible test result may be readily observed by the person performing the test in a prompt manner and under test conditions conducive to highly reliable and consistent test results. After initial specimen collection, human contact with the specimen is thus substantially precluded throughout the test protocol, and the entire device with the collected specimen safely contained therein may be discarded as a unit when the test is concluded.
  • While the invention has been described in detail with respect to the specific embodiments thereof, it will be appreciated that those skilled in the art, upon attaining an understanding of the foregoing, may readily conceive of alterations to, variations of, and equivalents to these embodiments. Accordingly, the scope of the present invention should be assessed as that of the appended claims and any equivalents thereto.

Claims (7)

1-20. (canceled)
21. A method for detecting the presence or absence of an analyte within a test sample, said method comprising:
i) providing a diagnostic test system, said system comprising a swab and a detection unit, said detection unit comprising:
a) a first component that is capable of receiving said swab, said first component defining an insertion chamber within which a fluid is retained; and
b) a second component that defines a detection chamber within which an assay for detecting the presence or absence of the analyte is contained;
ii) contacting said swab with the test sample;
iii) inserting said swab into said insertion chamber of said first component so that said swab contacts said fluid; and
iv) rotating said first component relative to said second component so that said fluid flows from said insertion chamber to said detection chamber and contacts said assay.
22. A method as defined in claim 21, wherein said first component defines a sample port through which said swab is inserted.
23. A method as defined in claim 22, wherein said detection unit further comprises a hydraulic seal that forms a sealing fit between said sample port and said swab.
24. A method as defined in claim 21, wherein a flexible packet is contained within said insertion chamber that retains said fluid, said swab rupturing said flexible packet when inserted into said insertion chamber.
25. A method as defined in claim 21, further comprising determining the intensity of a detection signal generated at a detection zone of said assay, wherein the amount of the analyte within the test sample is determined from said detection signal.
26. A method as defined in claim 25, further comprising calibrating said detection signal with a calibration signal generated at a calibration zone of said assay, wherein the amount of the analyte within the test sample is determined from said detection signal as calibrated by said calibration signal.
US12/982,452 2003-12-23 2010-12-30 Swab-Based Diagnostic Systems Abandoned US20110097820A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/982,452 US20110097820A1 (en) 2003-12-23 2010-12-30 Swab-Based Diagnostic Systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/744,607 US7863053B2 (en) 2003-12-23 2003-12-23 Swab-based diagnostic systems
US12/982,452 US20110097820A1 (en) 2003-12-23 2010-12-30 Swab-Based Diagnostic Systems

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/744,607 Continuation US7863053B2 (en) 2003-12-23 2003-12-23 Swab-based diagnostic systems

Publications (1)

Publication Number Publication Date
US20110097820A1 true US20110097820A1 (en) 2011-04-28

Family

ID=34678912

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/744,607 Expired - Fee Related US7863053B2 (en) 2003-12-23 2003-12-23 Swab-based diagnostic systems
US12/982,452 Abandoned US20110097820A1 (en) 2003-12-23 2010-12-30 Swab-Based Diagnostic Systems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/744,607 Expired - Fee Related US7863053B2 (en) 2003-12-23 2003-12-23 Swab-based diagnostic systems

Country Status (1)

Country Link
US (2) US7863053B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065297A1 (en) * 2014-10-23 2016-04-28 Ibis Biosciences, Inc. Swab port for microfluidic devices
US10119968B2 (en) 2012-06-02 2018-11-06 Test Anywhere Technology Self-contained diagnostic test with advanceable test strip

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9554736B2 (en) 2011-11-29 2017-01-31 Teleflex Medical Incorporated Device with integrated allergy testing
GB201201645D0 (en) * 2012-01-31 2012-03-14 Ge Healthcare Ltd Improvements in and relating to biological sample collection
WO2021252810A1 (en) 2020-06-10 2021-12-16 Checkable Medical Incorporated In vitro diagnostic device
CN113456116A (en) * 2021-06-06 2021-10-01 江西科伦医疗器械制造有限公司 Separation and reuse biological sample collection swab

Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3792699A (en) * 1972-05-30 1974-02-19 Medex Inc Disposable swab unit
US4168146A (en) * 1975-01-27 1979-09-18 Ab Kabi Immunoassay with test strip having antibodies bound thereto
US4235601A (en) * 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4386128A (en) * 1980-02-06 1983-05-31 Yutaka Yoshikawa Heat insulating laminate
US4442204A (en) * 1981-04-10 1984-04-10 Miles Laboratories, Inc. Homogeneous specific binding assay device and preformed complex method
US4447526A (en) * 1981-04-20 1984-05-08 Miles Laboratories, Inc. Homogeneous specific binding assay with carrier matrix incorporating specific binding partner
US4458020A (en) * 1982-11-15 1984-07-03 Quidel Integrated single tube plunger immunoassay system having plural reagent chambers
US4707450A (en) * 1986-09-25 1987-11-17 Nason Frederic L Specimen collection and test unit
US4831840A (en) * 1987-09-10 1989-05-23 Fletcher Charles J Ice maker with covered ice tray
US4952204A (en) * 1988-08-10 1990-08-28 Gam-Med Packaging Corporation Dry handle swab assembly and unit
US5084245A (en) * 1988-11-07 1992-01-28 Hygeia Sciences, Inc. Assay device for swab borne analytes
US5129402A (en) * 1991-02-19 1992-07-14 Accu-Med Corporation Apparatus for collecting and/or growing protected biological specimens
US5137808A (en) * 1987-04-07 1992-08-11 Syntex (U.S.A.) Inc. Immunoassay device
US5208535A (en) * 1990-12-28 1993-05-04 Research Development Corporation Of Japan Mr position detecting device
US5238649A (en) * 1988-02-09 1993-08-24 Nason Frederic L Specimen test unit
US5250412A (en) * 1987-03-23 1993-10-05 Diamedix Corporation Swab device and method for collecting and analyzing a sample
US5266266A (en) * 1988-02-09 1993-11-30 Nason Frederic L Specimen test unit
US5278075A (en) * 1989-02-02 1994-01-11 Hybrivet Systems, Inc. Test swab to detect a substance on a surface and method of making and using same
US5295952A (en) * 1991-06-19 1994-03-22 Surgical Innovations, Inc. Swab for laparoscopy
US5364792A (en) * 1989-02-02 1994-11-15 Hybrivet Systems, Inc. Test swab and method of making and using same
US5395754A (en) * 1992-07-31 1995-03-07 Hybritech Incorporated Membrane-based immunoassay method
US5449071A (en) * 1993-10-28 1995-09-12 Levy; Abner Tray for medical specimen collection kit
US5449494A (en) * 1991-07-02 1995-09-12 Amersham International Plc. Sampling device
US5508171A (en) * 1989-12-15 1996-04-16 Boehringer Mannheim Corporation Assay method with enzyme electrode system
US5534132A (en) * 1995-05-04 1996-07-09 Vreeke; Mark Electrode and method for the detection of an affinity reaction
US5550061A (en) * 1989-02-02 1996-08-27 Hybrivet Systems, Inc. Test swab and method of using same
US5660990A (en) * 1995-08-18 1997-08-26 Immunivest Corporation Surface immobilization of magnetically collected materials
US5670381A (en) * 1988-01-29 1997-09-23 Abbott Laboratories Devices for performing ion-capture binding assays
US5869003A (en) * 1998-04-15 1999-02-09 Nason; Frederic L. Self contained diagnostic test unit
US5879635A (en) * 1997-03-31 1999-03-09 Nason; Frederic L. Reagent dispenser and related test kit for biological specimens
US5917592A (en) * 1997-02-28 1999-06-29 Charm Sciences, Inc. Photometer, and test sample holder for use therein, method and system
US5983438A (en) * 1998-03-13 1999-11-16 Sony Corporation Sputter load lock O-ring cleaner
US6043047A (en) * 1993-04-23 2000-03-28 Celsis International, Plc Sample-collecting and assay device for use in the detection of biological material
US6194220B1 (en) * 1996-09-25 2001-02-27 Becton, Dickinson And Company Non-instrumented assay with quantitative and qualitative results
US6197254B1 (en) * 1999-01-11 2001-03-06 International Food Protection Self-contained assaying apparatus
US6241863B1 (en) * 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes
US6248294B1 (en) * 1998-04-15 2001-06-19 Frederic L. Nason Self contained diagnostic test unit
US6270637B1 (en) * 1997-12-05 2001-08-07 Roche Diagnostics Corporation Electrochemical biosensor test strip
US6281006B1 (en) * 1998-08-24 2001-08-28 Therasense, Inc. Electrochemical affinity assay
US6309818B1 (en) * 2000-02-01 2001-10-30 The United States Of America As Represented By The Department Of Health & Human Services Scratch wound assay device
US6352863B1 (en) * 1990-01-19 2002-03-05 La Mina, Inc. Assay device
US6406451B1 (en) * 2001-05-24 2002-06-18 Zila, Inc. Dry handle swab assembly
US6436651B1 (en) * 1997-12-16 2002-08-20 Kimberly-Clark Worldwide, Inc. Optical diffraction biosensor
US6461496B1 (en) * 1998-10-08 2002-10-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US20020173047A1 (en) * 2001-05-18 2002-11-21 Hudak Robert Thomas In line test device and methods of use
US6524530B1 (en) * 1997-10-13 2003-02-25 Kikkoman Corporation Sample collecting member and wiping inspection instrument
US6541194B2 (en) * 2000-03-31 2003-04-01 Neogen Corporation Method for the detection of the presence of chemical species known to inhibit a chemiluminescent reaction
US6548018B2 (en) * 2000-03-31 2003-04-15 Neogen Corporation Apparatus for chemiluminescent assays
US20030119202A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US6613576B1 (en) * 2002-01-15 2003-09-02 Sandia Corporation Field kit and method for testing for the presence of gunshot residue
US6991898B2 (en) * 2003-10-20 2006-01-31 Kimberly-Clark Worldwide, Inc. Diagnostic test device and method of using same
US20090117665A1 (en) * 2003-11-14 2009-05-07 Inverness Medical Switzerland Gmbh Rapid sample collection and analysis device and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000193A (en) 1988-08-01 1991-03-19 Adi Diagnostics Inc. Medical swab device
GB9405590D0 (en) 1994-03-22 1994-05-11 Celsis Ltd Assay device
WO1996014570A1 (en) 1994-11-07 1996-05-17 Idexx Laboratories, Inc. Self-contained signal generating sampling device and methods of use of same
CA2226857C (en) * 1995-07-12 2008-03-18 Charm Sciences, Inc. Test apparatus, system and method for the detection of test samples
GB9526204D0 (en) 1995-12-21 1996-02-21 Biotrace Ltd Sampling and assay device
GB9626101D0 (en) 1996-12-16 1997-02-05 Celsis Int Plc Assay device
US20020136665A1 (en) 2001-02-21 2002-09-26 Hayton Anthony John Swab assembly

Patent Citations (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3792699A (en) * 1972-05-30 1974-02-19 Medex Inc Disposable swab unit
US4168146A (en) * 1975-01-27 1979-09-18 Ab Kabi Immunoassay with test strip having antibodies bound thereto
US4235601A (en) * 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4386128A (en) * 1980-02-06 1983-05-31 Yutaka Yoshikawa Heat insulating laminate
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4366241B1 (en) * 1980-08-07 1988-10-18
US4442204A (en) * 1981-04-10 1984-04-10 Miles Laboratories, Inc. Homogeneous specific binding assay device and preformed complex method
US4447526A (en) * 1981-04-20 1984-05-08 Miles Laboratories, Inc. Homogeneous specific binding assay with carrier matrix incorporating specific binding partner
US4458020A (en) * 1982-11-15 1984-07-03 Quidel Integrated single tube plunger immunoassay system having plural reagent chambers
US4707450A (en) * 1986-09-25 1987-11-17 Nason Frederic L Specimen collection and test unit
US5250412A (en) * 1987-03-23 1993-10-05 Diamedix Corporation Swab device and method for collecting and analyzing a sample
US5137808A (en) * 1987-04-07 1992-08-11 Syntex (U.S.A.) Inc. Immunoassay device
US4831840A (en) * 1987-09-10 1989-05-23 Fletcher Charles J Ice maker with covered ice tray
US5670381A (en) * 1988-01-29 1997-09-23 Abbott Laboratories Devices for performing ion-capture binding assays
US5266266A (en) * 1988-02-09 1993-11-30 Nason Frederic L Specimen test unit
US5238649A (en) * 1988-02-09 1993-08-24 Nason Frederic L Specimen test unit
US4952204A (en) * 1988-08-10 1990-08-28 Gam-Med Packaging Corporation Dry handle swab assembly and unit
US5084245A (en) * 1988-11-07 1992-01-28 Hygeia Sciences, Inc. Assay device for swab borne analytes
US5330917A (en) * 1989-02-02 1994-07-19 Hybrivet Systems, Inc. Test swab device and method of detecting lead, mercury, arsenic, and bismuth
US5278075A (en) * 1989-02-02 1994-01-11 Hybrivet Systems, Inc. Test swab to detect a substance on a surface and method of making and using same
US5364792A (en) * 1989-02-02 1994-11-15 Hybrivet Systems, Inc. Test swab and method of making and using same
US5550061A (en) * 1989-02-02 1996-08-27 Hybrivet Systems, Inc. Test swab and method of using same
US5508171A (en) * 1989-12-15 1996-04-16 Boehringer Mannheim Corporation Assay method with enzyme electrode system
US6352863B1 (en) * 1990-01-19 2002-03-05 La Mina, Inc. Assay device
US5208535A (en) * 1990-12-28 1993-05-04 Research Development Corporation Of Japan Mr position detecting device
US5129402A (en) * 1991-02-19 1992-07-14 Accu-Med Corporation Apparatus for collecting and/or growing protected biological specimens
US5295952A (en) * 1991-06-19 1994-03-22 Surgical Innovations, Inc. Swab for laparoscopy
US5449494A (en) * 1991-07-02 1995-09-12 Amersham International Plc. Sampling device
US5395754A (en) * 1992-07-31 1995-03-07 Hybritech Incorporated Membrane-based immunoassay method
US6043047A (en) * 1993-04-23 2000-03-28 Celsis International, Plc Sample-collecting and assay device for use in the detection of biological material
US5449071A (en) * 1993-10-28 1995-09-12 Levy; Abner Tray for medical specimen collection kit
US5534132A (en) * 1995-05-04 1996-07-09 Vreeke; Mark Electrode and method for the detection of an affinity reaction
US5660990A (en) * 1995-08-18 1997-08-26 Immunivest Corporation Surface immobilization of magnetically collected materials
US6194220B1 (en) * 1996-09-25 2001-02-27 Becton, Dickinson And Company Non-instrumented assay with quantitative and qualitative results
US5917592A (en) * 1997-02-28 1999-06-29 Charm Sciences, Inc. Photometer, and test sample holder for use therein, method and system
US5879635A (en) * 1997-03-31 1999-03-09 Nason; Frederic L. Reagent dispenser and related test kit for biological specimens
US6524530B1 (en) * 1997-10-13 2003-02-25 Kikkoman Corporation Sample collecting member and wiping inspection instrument
US6270637B1 (en) * 1997-12-05 2001-08-07 Roche Diagnostics Corporation Electrochemical biosensor test strip
US6436651B1 (en) * 1997-12-16 2002-08-20 Kimberly-Clark Worldwide, Inc. Optical diffraction biosensor
US5983438A (en) * 1998-03-13 1999-11-16 Sony Corporation Sputter load lock O-ring cleaner
US5869003A (en) * 1998-04-15 1999-02-09 Nason; Frederic L. Self contained diagnostic test unit
US6248294B1 (en) * 1998-04-15 2001-06-19 Frederic L. Nason Self contained diagnostic test unit
US6241863B1 (en) * 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes
US6281006B1 (en) * 1998-08-24 2001-08-28 Therasense, Inc. Electrochemical affinity assay
US6461496B1 (en) * 1998-10-08 2002-10-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6197254B1 (en) * 1999-01-11 2001-03-06 International Food Protection Self-contained assaying apparatus
US6309818B1 (en) * 2000-02-01 2001-10-30 The United States Of America As Represented By The Department Of Health & Human Services Scratch wound assay device
US6548018B2 (en) * 2000-03-31 2003-04-15 Neogen Corporation Apparatus for chemiluminescent assays
US6541194B2 (en) * 2000-03-31 2003-04-01 Neogen Corporation Method for the detection of the presence of chemical species known to inhibit a chemiluminescent reaction
US20020173047A1 (en) * 2001-05-18 2002-11-21 Hudak Robert Thomas In line test device and methods of use
US6565808B2 (en) * 2001-05-18 2003-05-20 Acon Laboratories Line test device and methods of use
US6406451B1 (en) * 2001-05-24 2002-06-18 Zila, Inc. Dry handle swab assembly
US20030119202A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US6613576B1 (en) * 2002-01-15 2003-09-02 Sandia Corporation Field kit and method for testing for the presence of gunshot residue
US6991898B2 (en) * 2003-10-20 2006-01-31 Kimberly-Clark Worldwide, Inc. Diagnostic test device and method of using same
US20090117665A1 (en) * 2003-11-14 2009-05-07 Inverness Medical Switzerland Gmbh Rapid sample collection and analysis device and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10119968B2 (en) 2012-06-02 2018-11-06 Test Anywhere Technology Self-contained diagnostic test with advanceable test strip
WO2016065297A1 (en) * 2014-10-23 2016-04-28 Ibis Biosciences, Inc. Swab port for microfluidic devices

Also Published As

Publication number Publication date
US20050136479A1 (en) 2005-06-23
US7863053B2 (en) 2011-01-04

Similar Documents

Publication Publication Date Title
US7098040B2 (en) Self-contained swab-based diagnostic systems
US8377379B2 (en) Lateral flow assay device
US7651841B2 (en) Polyelectrolytic internal calibration system of a flow-through assay
AU2007280929B2 (en) Analysis device for biological sample
CA1309654C (en) Membrane assay using focused sample application
US8137985B2 (en) Polyelectrolytic internal calibration system of a flow-through assay
US7662643B2 (en) Reduction of the hook effect in membrane-based assay devices
US8124421B2 (en) Flow control technique for assay devices
EP1459068B1 (en) Internal calibration system for flow-through assays
US20110097820A1 (en) Swab-Based Diagnostic Systems
WO2006036247A1 (en) Detecting yeast infections using a lateral flow assay
US20050191704A1 (en) Assay devices utilizing chemichromic dyes
EP3833735A1 (en) Lateral flow immunoassay device with separation membrane
WO2003058246A1 (en) Flow-through assay with an internal calibration system using polyelectrolyte
US9535061B1 (en) Multi-functional rapid diagnostic test device
US7713748B2 (en) Method of reducing the sensitivity of assay devices
JPH0552757U (en) Inspection tool
MXPA06007296A (en) Self-contained swab-based diagnostic systems

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE